Loading clinical trials...
Loading clinical trials...
In this prospective cohort study, investigators will conduct ultrasound surveillance of the nodal basins of patients with head and neck cutaneous squamous cell carcinoma (cSCC) whose tumors are considered high risk and staged by the Brigham and Women's Hospital (BWH) tumor staging system. The study will enroll patients with tumors staged T2a and who are also immunosuppressed (from solid organ transplant, hematologic malignancy or autoimmune disease), T2b (sentinel lymph node negative), and T3 (sentinel lymph node negative). After two years of surveillance, outcomes regarding local recurrence, nodal metastasis, disease specific death, and overall survival will be compared with historical controls with the overall hypothesis that ultrasound surveillance will detect subclinical disease earlier and help improve outcomes.
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
Sibley Memorial Hospital
Washington D.C., District of Columbia, United States
Johns Hopkins Hospital
Baltimore, Maryland, United States
Start Date
February 1, 2024
Primary Completion Date
May 14, 2025
Completion Date
May 14, 2025
Last Updated
March 9, 2026
1
ACTUAL participants
Ultrasound
DIAGNOSTIC_TEST
Lead Sponsor
Johns Hopkins University
NCT05075980
NCT06823479
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions